I received my PhD in Rheumatology, studying the effect of Matrix Metalloproteinases (MMPs) on cartilage destruction, from University of Newcastle-upon-Tyne (2003), and moved to Division of Therapeutics & Molecular Medicine, University of Nottingham, to research MMPs in Airway Remodelling until 2006. After that, I joined AstraZeneca Charnwood (2006–2010), working within a GLP/GCP department, developing & validating ligand-binding-assays and analysing biomarkers in clinical samples, before moving to the AZ Personalised Healthcare & Biomarker group in Gothenburg, Sweden continuing with the challenge of biomarker analysis. In 2015, I joined the newly formed Nucleotide Bioanalysis Group (Gothenburg) providing analytical support to the progression of New Modality (Oligonucleotide) therapeutics in pre-clinical models.
Click here to go back.
